This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Soblidotin

Yakult Honsha Co. Ltd.

Drug Names(s): TZT-1027, YHI-501

Description: TZT-1027 is a novel synthesized dolastatin 10 derivative that is an inhibitor of tubulin polymerization. Dolastatin 10 is a pentapeptide isolated from the marine mollusk Dolabella auricularia.

Deal Structure: Soblidotin was originally developed by Teikoku Hormone Manufacturing Company, Limited.

In December 2000, Daiichi Pharmaceutical signed a licensing agreement with Teikoku Hormone Mfg. for TZT-1027.

On April 27, 2005, Teikoku Hormone announced that it has agreed with Daiichi Pharmaceutical to terminate the license agreement for TZT-1027 that they concluded in December 2000. From now on, Teikoku Hormone will seek new partners for further research.

On October 1, 2005, Teikoku Hormone Manufacturing Company and Grelan Pharmaceutical Company merged together to become ASKA Pharmaceutical Company, Limited.

In March 2007, ASKA Pharmaceutical and Yakult Honsha concluded the agreement on the license of Soblidotin. Under this agreement, Yakult has received the exclusive rights to develop and market Soblidotin worldwide (including Japan).


Soblidotin News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug